Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview

Corvus Pharmaceuticals

14/03/2025 20:58

Corvus Pharmaceuticals Inc CRVS.OQ CRVS.O is expected to show no change in quarterly revenue when it reports  results on March 17 (estimated) for the period ending December 31 2024

​LSEG's mean analyst estimate for Corvus Pharmaceuticals Inc is for a loss of 12 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Corvus Pharmaceuticals Inc is $13.00​, above​ its last closing price of $4.50. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.11
-0.12
-0.60
Missed
-414.6
Jun. 30 2024
-0.12
-0.11
-0.04
Beat
65.2
Mar. 31 2024
-0.14
-0.12
-0.12
Met
0​
Dec. 31 2023
-0.12
-0.14
Missed
-17.6
​​Sep. 30 2023
-0.12
-0.12
-0.12
Met
1.6
Jun. 30 2023
-0.16
-0.14
-0.14
Met
-0.5​
Mar. 31 2023
-0.16
-0.16
-0.17
Missed
-8.3
Dec. 31 2022
-0.25
-0.23
-0.21
Beat
9.1

This summary was machine generated March 14 at 20:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)